<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13311</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">MECHANISMS OF INTERACTION BETWEEN HIV AND MYCOPLASMA ARGININI IN VITRO</article-title><trans-title-group xml:lang="ru"><trans-title>МЕХАНИЗМЫ ВЗАИМОДЕЙСТВИЯ ВИЧ С MYCOPLASMA ARGININI IN VITRO</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Miller</surname><given-names>G. G</given-names></name><name xml:lang="ru"><surname>Миллер</surname><given-names>Г. Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rakovskaya</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Раковская</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pokidysheva</surname><given-names>L. N</given-names></name><name xml:lang="ru"><surname>Покидышева</surname><given-names>Л. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korablina</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Кораблина</surname><given-names>Е. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Titova</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Титова</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia</institution></aff><aff><institution xml:lang="ru">НИИ эпидемиологии и микробилогии им. Н.Ф.Гамалеи, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2009</year></pub-date><volume>86</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2009)</issue-title><issue-title xml:lang="ru">№4 (2009)</issue-title><fpage>49</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Miller G.G., Rakovskaya I.V., Pokidysheva L.N., Korablina E.V., Titova I.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Миллер Г.Г., Раковская И.В., Покидышева Л.Н., Кораблина Е.В., Титова И.В.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Miller G.G., Rakovskaya I.V., Pokidysheva L.N., Korablina E.V., Titova I.V.</copyright-holder><copyright-holder xml:lang="ru">Миллер Г.Г., Раковская И.В., Покидышева Л.Н., Кораблина Е.В., Титова И.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/13311">https://microbiol.crie.ru/jour/article/view/13311</self-uri><abstract xml:lang="en"><p>Aim. Until now, the problem of effective therapy of HIV-infection is not resolved due to integrative type of interaction of HIV virus with target cell — T-lymphocyte. The study was aimed on search of method of deletion of HIV DNA-provirus from cell's genome. Materials and methods. Non-pathogenic for humans Mycoplasma arginini was used for coinfection of HIV-infected cells in model systems in vitro . Results. Complex of mechanisms was documented leading to: blocking up to 50 — 60% of extracellular virus (according to titration results), cancel of apoptosis in infected cells stained on Hoechst, formation of defective vif virions, which together with arginine-desaminase of M.arginini arrange permissive conditions for activation of cellular APOBEC3G with subsequent disruption of DNA- provirus and blocking of viral infection. As studies of ultrastructure showed, listed events resulted from direct interaction of HIV with mycoplasma. Conclusion. The elimination of HIV DNA-provirus is possible by co-infection of T-lymphocytes with M.arginini .</p></abstract><trans-abstract xml:lang="ru"><p>Цель. До настоящего времени не решена проблема эффективной терапии ВИЧ-инфекции из-за интеграционного типа его взаимодействия с клеткой мишенью — Т-лимфоцитом. Исследование направлено на поиск способа удаления из генома клетки ДНК-провируса ВИЧ. Материалы и методы. Использована не патогенная для человека микоплазма M.arginini для ко-инфекции ВИЧ-инфицированных клеток в модельных системах in vitro. Результаты . Документирован комплекс механизмов, приводящих: к блокированию до 50 — 60% внеклеточного вируса (по данным титрования), отмене микоплазмой апоптоза в инфицированных клетках, окрашенных по Hoechst, образованию дефектных vif(-) вирионов, которые вместе с аргинин–дезаминазой M.arginini создают разрешающие условия для активации клеточного APOBEC3G с последующим разрушением ДНКпровируса и блокированием вирусной инфекции. Как показали ультраструктурные исследования, перечисленные события являются результатом прямого взаимодействия ВИЧ с микоплазмой. З аключение. Возможна элиминация ДНК-провируса ВИЧ путем ко-инфекции Т-лимфоцитов микоплазмой M.arginini.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Mycoplasma arginini</kwd><kwd>human immunodeficiency virus</kwd><kwd>integrative infection</kwd><kwd>Mycoplasma arginini</kwd><kwd>mixed infection</kwd><kwd>elimination of HIV DNA-provirus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вирус иммунодефицита человека</kwd><kwd>интегративная инфекция</kwd><kwd>смешанная инфекция</kwd><kwd>элиминация ДНК-провируса ВИЧ</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Миллер Г.Г., Раковская И.В. Электронно-микроскопическое изучение ассоциации микоплазмы и бычьего лейкозного вируса в культуре ткани. Вопр. вирусол. 1983, 5: 615-621.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Покровский В.В., Ермак Т.Н., Беляева В.В. и др. ВИЧ-инфекция, клиника, диагностика, лечение. М., ГЕОТАР Медицина, 2000.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Del Real G. et al. Transmembrane Lipid-enriched domains promote the HIV bound up with CD4 Receptors. J. Exp. Med. 2002, 196: 293-301.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Goff S.P. Death by deamination: a novel host restriction system for HIV-1. Cell. 2003, 114: 281-283.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lo Sh.-Ch. In: Molecular biology and pathogenisity of mycoplasmas. Sh.Razin, R.Hermann (ed.). N.Y., 2002, p. 187-203.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lo Sh.-Ch., Dawson M.S., Wong D.M. et al. Novel mycoplasma, which enhance AIDS progression. Am. J. Trop. Med. Hyg. 1992, 41 (5): 601-616.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Mangeat B., Turelli P., Caron G. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003, 424: 99-103.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Muhlradt P.F. Immunomodulation of mycoplasmas: artifacts, facts and active molecules. In: Molecular biology and pathogenisity of mycoplasmas. Sh.Razin, R. Hermann, (ed.). N.Y., 2002, p. 445-472.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rakovskaya I., Miller G. Putative significance of mycoplasmas in the AIDS pathogenesis. Lett. Ames, Iowa, 1992, 2: 2-7.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sheehy A.M., Gaddis N.C., Choi J.D. et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002, 418: 646-650.</mixed-citation></ref></ref-list></back></article>
